# AgomAb Therapeutics NV (AGMB) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $6.85, market value $337 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). AgomAb Therapeutics NV reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 2.7×**. The shares trade at 2.7× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -15.3%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -47.8%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -0.5%**. Earnings per share fell 0.5%.

## Financial health
- **Debt to equity: 0.01**. Debt is 0.01 times equity: a conservative balance sheet.
- **Current ratio: 6.52** (quick 6.52). Current assets cover the next year's liabilities 6.52 times.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. AgomAb Therapeutics NV does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (6 analysts). 6 analysts cover AgomAb Therapeutics NV; the consensus is strong_buy, with an average price target of $37.67 (+450% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -61.6%** (5.1% above the low). Trading 62% below its 52-week high, deep in a drawdown.
- **RSI (14-day): 25**. An RSI of 25 is oversold; bounces are common, but oversold can stay oversold in a real decline.
- **Beta (1 yr): 1.64** (volatility 91%). Beta of 1.64 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AGMB · Page: https://foliofundamentals.com/stocks/agmb

Not investment advice.